Optimizing Respiratory Therapy Resources by De-Implementing Low-Value Care

• Published in: Respiratory care 2023-05, Vol.68 (5), p.559-564
• Main Authors: Fleming, Kellianne, George, Jessica L, Bazelak, Sarah J, Roeske, Julie A, Biggs, Adam D, Landry, Curtis M, Lipchik, Randolph J, Truwit, Jonathon D
• Format: Article
• Language: English
• Subjects: Acetylcysteine; COVID-19 - therapy; Editor's Choice; Evaluation; Health care industry; Human resource management; Humans; Low-Value Care; Management; Pandemics; Practice guidelines (Medicine); Respiratory therapists; Respiratory Therapy; Training
• ISSN: 0020-1324; 1943-3654
• DOI: 10.4187/respcare.10712

Our institution was experiencing a respiratory therapy staffing crisis during the COVID-19 pandemic, in part due to excessive workload. We identified an opportunity to reduce burden by limiting use of 3% hypertonic saline and/or N-acetylcysteine nebulizer therapies (3%HTS/NAC). Leveraging the science of de-implementation, we established a policy empowering respiratory therapists to discontinue 3%HTS/NAC not meeting the American Association for Respiratory Care (AARC) Clinical Practice Guideline: Effectiveness of Pharmacologic Airway Clearance Therapies in Hospitalized Patients. After a 3-month period of educating physicians and advanced practice practitioners the policy went to into effect. Outcomes measured included monthly number of treatments, orders, and full-time employees associated with administering nebulized 3%HTS/NAC. Post policy activation, the monthly mean 3%HTS/NAC treatments were significantly reduced to 547.5 ± 284.3 from 3,565.2 ± 596.4 ( < .001) as were the associated monthly mean of full-time employees, 0.8 ± 0.41 from 5.1 ± 0.86 ( < .001). The monthly mean 3%HTS/NAC orders also fell to 93.8 ± 31.5 from 370.0 ± 46.9 ( < .001). Monthly mean non-3%HTS/NAC treatments remained stable; post policy was 3,089.4 ± 611.4 and baseline 3,279.6 ± 695.0 ( = 1.0). Implementing a policy that empowers respiratory therapists to promote adherence to AARC Clinical Guidelines reduced low-value therapies, costs, and staffing needs.